Biopharmaceutical research companies are conducting or have conducted more than 560 clinical trials of new medicines in collaboration with the state’s university medical school, clinical research centers and hospitals (1999 to present).

Of the more than 560 clinical trials, 365 target the nation’s six most debilitating chronic diseases— asthma, cancer, diabetes, heart disease, mental illnesses and stroke.

“Vermont is committed to good health for people, our environment, and our institutions including our schools, colleges and universities, our businesses and our cities and communities. One significant health care effort that doesn’t receive the attention it deserves is the active research activity of local research institutions—from Chittenden County to White River Junction, from Brattleboro to Bennington. Many of these institutions are members of the Vermont Biosciences Alliance. Working often in partnership with NIH and most major pharmaceutical companies, our research efforts are contributing to the development of life saving drugs, devices, and treatments. No one researcher or institution can single handedly develop a drug or a medical device. It requires capital, talent, drive, initiative and teamwork. Some of the things for which Vermont is known.” --Bill Church, President of Green Mountain Antibodies; Chair, Vermont Biosciences Alliance (VBSA)